Search KRYS
Krystal Biotech, Inc.
Nasdaq · CIK 1711279
Last close322.28
Daily change-3.03 (-0.93%)
10 Years gain+2928.95%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
KRYS · STANDARD
SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 1231
Fundamental
80.6Momentum
100.0Acceleration
100.0Confidence
77.0Annual Revenue5
Quarterly Revenue12
Annual CFO8
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth25.0 / 25
Quality17.2 / 25
Capital Efficiency19.4 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 23.84 percentage points.
ROIC expansionROIC improved by 11.9107 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Strong operating leverageOperating income is growing faster than revenue while operating margin expands.
Key Metrics
Revenue Growth TTM49.33%OK
Revenue CAGR 3Yn/aINSUFFICIENT_HISTORY
Gross Margin100%OK
Operating Margin44.92%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC24.15%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y2.63%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $389.13M | $389.13M | $161.30M | $200.87M | $188.91M | 100% | 41.45% | 48.55% | 40.03% | 29.95M |
| 2025 FY Dec 31, 2024 | $290.52M | $290.52M | $65.75M | $123.42M | $119.18M | 100% | 22.63% | 41.02% | 20.65% | 29.74M |
| 2025 FY Dec 31, 2023 | $50.70M | $50.70M | -$109.62M | -$88.80M | -$100.60M | 100% | -216.21% | -198.43% | -47.71% | 27.75M |
| 2024 FY Dec 31, 2022 | $0.00 | $0.00 | -$145.20M | -$100.57M | -$153.55M | n/a | n/a | n/a | -76.84% | 25.49M |
| 2023 FY Dec 31, 2021 | $0.00 | $0.00 | -$68.28M | -$47.94M | -$116.27M | n/a | n/a | n/a | -61.19% | 22.2M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $429.42M | sum latest 4 fiscal quarters Revenue | OK | 0001711279-26-000057, 0001711279-25-000087 |
| Revenue Growth TTM | 49.33% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001711279-26-000057, 0001711279-25-000087 |
| Revenue CAGR 3Y | n/a | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001711279-26-000016 |
| Revenue CAGR 5Y | n/a | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | INSUFFICIENT_HISTORY | 0001711279-26-000016 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001711279-26-000016 |
| Operating Income Growth | 218.25% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0001711279-26-000057, 0001711279-25-000087 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0001711279-26-000057, 0001711279-25-000087 |
| Operating Margin | 44.92% | Operating Income / Revenue | OK | 0001711279-26-000057, 0001711279-25-000087 |
| ROIC | 24.15% | NOPAT / Average Invested Capital | OK | 0001711279-26-000057, 0001711279-25-000087 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001711279-26-000057 |
| Current Ratio | 8.32x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $14.01 | Revenue / Diluted Shares | OK | 0001711279-26-000057, 0001711279-25-000087 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |